Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck

Guojun Li, Zhensheng Liu, Erich M. Sturgis, Robert M. Chamberlain, Margaret R. Spitz and Qingyi Wei
Guojun Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhensheng Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erich M. Sturgis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Chamberlain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret R. Spitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingyi Wei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-04-0814 Published April 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • NQO1
  • CYP2E1
  • CYP1B1
  • genetic susceptibility
  • molecular epidemiology

Introduction

Tobacco use and alcohol consumption are the major risk factors for squamous cell carcinoma of the head and neck (SCCHN; ref. 1). Polymorphisms in tobacco carcinogen– and alcohol-metabolizing genes may contribute to variation in enzyme activities and, thus, influence individual susceptibility to SCCHN.

Cytochrome P450 2E1 (CYP2E1) is a phase I enzyme that catalyzes metabolic activation of several compounds found in cigarette smoke, such as N-nitroso-dimethylamine, benzene, N-nitrosonornicotine (2), and ethanol (3). More than 25 polymorphisms of CYP2E1 have been identified,3 one of which is G1532C located upstream of the CYP2E1 transcription start site that is believed to affect CYP2E1 expression (3).

Cytochrome P450 1B1 (CYP1B1) is another phase I enzyme that activates tobacco-related carcinogens, such as polycyclic aromatic hydrocarbons and aromatic amines (4). Among the eight potential functional polymorphisms,3 a G-to-A substitution resulting in an amino acid change from valine to leucine at codon 432 (V432L) may alter catalytic efficiency for the 4-hydroxylation (,5).

NAD(P)H:quinone oxidoreductase 1 (NQO1), a cytosolic two-electron reductase (a phase II enzyme), catalyzes reductive activation of carcinogens from cigarette smoke, such as nitrosamines and heterocyclic amines (6), and protects cells against oxidative damage from reactive oxygen species (7). Among 14 documented polymorphisms, one functional polymorphism, a C-to-T substitution at nucleotide 609 of exon 6, causes an amino acid change from proline to serine at codon 187 (P187S; ref. 8), resulting in a loss of NQO1 activity (9).

Previously published association studies have led to examination of CYP2E1, NQO1, and CYP1B1 polymorphisms in relation to the risk of some tobacco-related carcinomas but only few relatively small studies have examined SCCHN risk. To further verify the possible roles of these polymorphisms in the etiology of SCCHN, we investigated the associations between these three functional polymorphisms and the risk of SCCHN in a large hospital-based, case-control study in a non-Hispanic White population.

Materials and Methods

Study Population

Cases were patients with newly diagnosed, histologically confirmed, previously untreated SCCHN seen at the University of Texas M. D. Anderson Cancer Center between May 1995 and October 2003 (10). Cancer-free controls were hospital visitors who were genetically unrelated to the SCCHN patients and were frequency-matched with cases for age (±5 years), sex, and smoking status (current, former, and never), and ethnicity. After informed consent was obtained, a blood specimen was obtained from each study subject.

Control subjects were from among two populations: 602 enrollees in the Kelsey Seybold Foundation, a multispecialty physician practice with multiple clinics throughout the Houston metropolitan area (11), and 624 visitors to M. D. Anderson Cancer Center who were accompanying patients to our outpatient clinics. To minimize selection bias in either control group in terms of genotypes and unknown confounders and to increase the study power, we combined these subgroups into a single control group in the final analysis after we had found no differences in the frequency distributions of the CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu genotypes between the two subgroups (χ2 = 3.18, P = 0.204; χ2 = 0.103, P = 0.950; and χ2 = 1.99, P = 0.370; respectively).

Genotyping

DNA was extracted from the buffy coat of whole blood with the Qiagen DNA Blood Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Genotyping was done by using published primer sequences and PCR-RFLP methods for CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms (12-14). More than 10% of the samples were randomly selected for repeat genotyping and the results were in 100% concordance.

Statistical Analysis

We assessed the associations between genetic polymorphisms and risk of SCCHN after controlling for age, sex, and other potential confounding factors by computing odds ratios (OR) and 95% confidence intervals (95% CI) from unconditional logistic regression analyses using SAS software (SAS version 8.2, SAS Institute, Inc., Cary, NC).

Results

Cases were 724 non-Hispanic Whites (74.7% male) with SCCHN of the oral cavity (224, 30.9%), pharynx (325, 44.9%), or larynx (175, 24.2%); controls were 1,226 non-Hispanic cancer-free Whites (73.9% male). Mean (±SD) age was not different between the cases (57.1 ± 11.9) and the controls (57.1 ± 11.6; P = 0.983). Frequency distributions of CYP2E1, NQO1, and CYP1B1 genotypes and their associations with SCCHN risk are shown in Table 1. Distributions of these genotypes and allele frequencies were not significantly different between cases and controls, and the genotypes in the controls were in Hardy-Weinberg equilibrium (P = 0.314, CYP2E1; P = 0.087, NQO1; and P = 0.359, CYP1B1; respectively). No significant associations between genetic polymorphisms of CYP2E1, NQO1, and CYP1B1 and risk of SCCHN were observed after adjustment for age, sex, and smoking and alcohol status (Table 1). We then stratified the data by cancer sites, smoking and alcohol status, age, and sex, but did not find any evidence of associations between the genotypes and SCCHN risk among these subgroups (data not shown). Furthermore, we found no evidence of any interaction between CYP2E1, NQO1, and CYP1B1 genotypes and other covariates (data not shown).

View this table:
  • View inline
  • View popup
Table 1.

SCCHN risk associated with CYP1B1 V432L, CYP2E1 G1532C, and NQO1 P187S polymorphisms

For this analysis, we had an 80% power (two-sided test, α = 0.05) to detect an OR of 0.71 or 1.41 for CYP1B1 Leu/Leu homozygotes (20.9% in the controls) if the variant genotype was a protective or risk genotype compared with the CYP1B1 Val/Val + Val/Leu genotype, assuming a recessive allele model. Similarly, for CYP1B1 variant genotypes (Val/Val + Val/Leu, 70.2% in the controls), the detectable OR was 0.76 or 1.31 compared with the Val/Val genotype, assuming a dominant allele model. For the combined CYP2E1 CG + CC (7.35% in the controls) and NQO1 Ser/Pro + Ser/Ser (34.3% in the controls) genotypes, we had an 80% power (two-sided test, α = 0.05) to detect an OR of 0.56 or 1.79 and 0.75 or 1.33 compared with the CYP2E1 GG and NQO1 Pro/Pro genotypes, respectively. Thus, our study had sufficient power to detect an OR of 0.78 (P > 0.05 for CYP1B1 Leu/Leu versus Val/Val genotype) reported in a study of 312 SCCHN cases and 300 controls by Ko et al. (15) and an OR of 0.87 (P > 0.05 for CYP2E1 CG + CC versus GG genotype) reported in a study of 75 SCCHN cases and 200 controls by Gonzalez et al. (12).

Discussion

Cancers of the lung, bladder, and head and neck are all tobacco related. Previous studies suggested that functional polymorphisms of CYP1B1, CYP2E1, and NQO1 were strongly associated with risk of lung and bladder carcinomas (16-19), but few studies have explored these polymorphisms as risk factors for SCCHN. In the present study, among non-Hispanic Whites, we found no evidence of an association between the CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms and SCCHN risk. Our findings suggest that these polymorphisms may not play a major role in the etiology of SCCHN.

To the best of our knowledge, ours is the largest molecular epidemiologic study of the association between these polymorphisms and SCCHN risk. Only two previous studies examined the CYP1B1 Val432Leu and CYP2E1 G1532C polymorphisms and the risk of SCCHN. Ko et al. (15) found that CYP1B1 Val432Leu polymorphism had no main effect (312 cases and 300 controls) but was a susceptibility factor among smokers, which was not confirmed by our study. The frequency of the CYP1B1 genotypes among our larger control group were 29.8% for the Val/Val genotype, 49.3% for Val/Leu genotype, and 20.9 for Leu/Leu genotype, compared with 36.3%, 46.0%, and 17.7% in the study by Ko et al. (15). The discrepancy in distribution may reflect differences in ethnic backgrounds of the two studies (European versus American Caucasians) or a chance finding in the study by Ko et al. in smokers of 195 cases and 177 controls compared with 536 cases and 857 controls who were smokers in our study. Another previous case-control study of 75 SCCHN cases and 200 controls showed that the CYP2E1 G1532C polymorphism was not associated with SCCHN risk (12), a finding we confirmed in this larger study. This finding is likely to be true because control subjects of both studies had similar frequencies of CYP2E1 G1532C polymorphism genotypes. To date, no reports have been published as to whether the NQO1 Pro187Ser polymorphism is associated with SCCHN risk. Our data did not support the hypothesis that this polymorphism had an effect on SCCHN risk, although one study found that individuals carrying 1 or 2 NQO1 609T alleles had a 2.85-fold higher risk for the development of esophageal adenocarcinoma (n = 61 versus 252 controls) and a 2.18-fold higher risk for cardiac adenocarcinoma (n = 120 versus 252 controls), respectively, than wild-type homozygotes (20). However, these positive findings may have been due to chance because of the small sample sizes, particularly in the subgroups; moreover, that study had higher Pro/Pro (73.4%) and lower Ser/Pro (25.0%) genotype frequencies among controls compared with 65.7% for Pro/Pro and 31.6% for Ser/Pro in our study.

The strengths of our study include the relatively large sample size of a single ethnic group for a relatively rare cancer and the study power to detect a reasonably small risk. The limitation of our study was the hospital-based study design with which we could not exclude the possibility of selection bias that may have masked a real association. Because the CYP2E1, NQO1, and CYP1B1 genes all have multiple putative functional polymorphisms, large population-based case-control studies with genotyping of more variants and subsequent haplotype analysis are warranted to understand the roles of these polymorphisms in the etiology of SCCHN.

Acknowledgments

We thank Margaret Lung, Peggy Schuber, and Leanel Fairly for their assistance in recruiting the subjects; Li-E Wang for technical support; Jianzhong He, John I. Calderon, and Kejin Xu for their laboratory assistance; Betty J. Larson for manuscript preparation; and Rachel Willims for scientific editing. This study was supported by National Institutes of Health grants ES 11740 (to Q.W.) and in part by CA 86390 and CA 97007 (to M.R.S. and W.K.H.). CA 16672 (to M.D. Anderson Cancer Center), and CA 57730 (to R.M.C.).

Footnotes

  • ↵3 http://snp500cancer.nci.nih.gov/snplist.cfm.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 19, 2004.
    • Received November 8, 2004.

References

  1. ↵
    Fanceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E. Smoking and drinking in relation to cancer of the oral cavity, pharynx, larynx and esophagus in northern Italy. Cancer Res 1990;50:6502–7.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992;13:1789–94.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559–65.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607–13.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440–4.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803–7.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res 2002;62:1420–4.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995;72:555–61.
    OpenUrlPubMed
  9. ↵
    Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997;75:69–75.
    OpenUrlPubMed
  10. ↵
    Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2004;25:1911–6.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764–72.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294–8.
    OpenUrlAbstract
  13. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 1994;375:439–45.
    OpenUrlPubMed
  14. ↵
    Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209–16.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398–404.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Choi JY, Lee KM, Cho SH, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003;13:349–55.
    OpenUrlCrossRefPubMed
  17. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999;59:3045–8.
    OpenUrlAbstract/FREE Full Text
  18. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87–92.
    OpenUrlAbstract
  19. ↵
    Wu X, Amos CI, Kemp BL, et al. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev 1998;7:13–8.
    OpenUrlAbstract
  20. ↵
    Sarbia M, Bitzer M, Siegel D, et al. Association between NAD(P)H: quinone oxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003;107:381–6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 14 (4)
April 2005
Volume 14, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Guojun Li, Zhensheng Liu, Erich M. Sturgis, Robert M. Chamberlain, Margaret R. Spitz and Qingyi Wei
Cancer Epidemiol Biomarkers Prev April 1 2005 (14) (4) 1034-1036; DOI: 10.1158/1055-9965.EPI-04-0814

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Guojun Li, Zhensheng Liu, Erich M. Sturgis, Robert M. Chamberlain, Margaret R. Spitz and Qingyi Wei
Cancer Epidemiol Biomarkers Prev April 1 2005 (14) (4) 1034-1036; DOI: 10.1158/1055-9965.EPI-04-0814
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Diet Quality and Ovarian Cancer Survival
  • PDE5 inhibitors use and precursors of colorectal cancer
  • Association between serum iron biomarkers and breast cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement